In 294 patients with untreated advanced EGFR- and TP53-mutated NSCLC, osimertinib plus pemetrexed–carboplatin lengthened median PFS vs osimertinib alone (34.0 vs 15.6 months; HR 0.44), with more grade ≥3 treatment-related adverse events. Overall survival is immature.
RCTn = 294
Zhou et al. Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial